---
title: Enable new Parkinson treatment development
nct_id: NCT06203106
status: RECRUITING
sponsor: New York Stem Cell Foundation Research Institute
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06203106"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06203106"
last_fetched: "2026-05-10T14:03:34.416Z"
source: "Parkinson's Pathways (curated)"
---
# Enable new Parkinson treatment development

**Goal (in five words):** Enable new Parkinson treatment development

**Official Title:** NYSCF Scientific Discovery Biobank

**Trial ID:** [NCT06203106](https://clinicaltrials.gov/study/NCT06203106)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** New York Stem Cell Foundation Research Institute
- **Target Enrollment:** 10000 participants
- **Start Date:** 2022-11-10
- **Completion Date:** 2045-11-10
- **Conditions:** ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
- **Interventions:** Biological Sample Collection
- **Intervention Types:** OTHER

## Summary For Families

The goal is to build a large, shared biobank of blood, saliva, skin, and transferred samples linked to medical data so researchers can speed up discovery of biomarkers and new treatments for Parkinson's and many other neurological and medical conditions. Participants provide samples that can be used to extract DNA, measure proteins, create induced pluripotent stem cell lines, and run lab studies to understand disease mechanisms or test experimental therapies. The study is open to people 30 days and older who have Parkinson's disease or other listed conditions, or who are healthy controls, with adults providing consent and people without decisional capacity allowed with assent plus a legally authorized representative consent. People who are wards of the state, who have certain bleeding or skin-healing problems relevant to sample collection, or who have AIDS with CD4 under 200 are excluded.

## Eligibility

- **Minimum age:** 30 Days
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age 30 days or older.
* Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control.
* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.
* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD/ADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and/or Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.
* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental/guardian consent.
* Minors undergoing blood, and/or saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent.
* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent.

Exclusion Criteria:

* Wards of the state.
* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.
* For prospective blood samples: history of coagulation disorder.
* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.
```

## Locations (1)

- New York Stem Cell Foundation Research Institute, New York, New York, United States _(40.7143, -74.0060)_
  - Clinical Research Office — (CONTACT) — 212-927-1801 — clinicalresearch@nyscf.org
  - Laura Andres-Martin, PhD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Clinical Research Office — (CONTACT) — 212-927-1801 — clinicalresearch@nyscf.org

---

*Canonical: https://parkinsonspathways.com/trial/NCT06203106*  
*HTML version: https://parkinsonspathways.com/trial/NCT06203106*  
*Source data: https://clinicaltrials.gov/study/NCT06203106*